The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

Importance Chronic lymphocytic leukemia (CLL), defined by a minimum of 5× 10 9/L
monoclonal B cells in the blood, affects more than 200 000 people and is associated with …

Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with
Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy …

Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this
first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3+ 3 dose …

Background Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as
monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21 …

Background Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma.
Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor …

The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to
relentless advances in molecular pathogenesis, prognostication, and newer treatments …

Purpose: Mantle-cell lymphoma (MCL) is an incurable mature B-cell neoplasm with high
initial response rates followed almost invariably by relapse. Prognosis for patients following …

Inhibition of Bruton's tyrosine kinase (BTK) has revolutionized the treatment landscape for
patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal …

Bruton's tyrosine kinase (BTK) was initially discovered as a critical mediator of B cell
receptor signaling in the development and functioning of adaptive immunity. Growing …